Citations

Clear

9383 citation(s) found for "Thomas, PS".

Perspectives of Oncologists on the Ethical Implications of Using Artificial Intelligence for Cancer Care
Walsh, Thomas , Kehl, Kenneth L. , Abel, Gregory A. , Sharp, Richard, Hantel, Andrew , Marron, Jonathan M. , Sharp, Richard R. , Van Allen, Eliezer M

Mayo Clinic

JAMA Network Open | March 28, 2024 | Volume: 7 | Issue: 3 | Pages: e244077

10.1001/jamanetworkopen.2024.4077 | PMID 38546644 Get It

Importance Artificial intelligence (AI) tools are rapidly integrating into cancer care. Understanding stakeholder views on ethical issues associated with the implementation of AI in oncology is critical to optimal deployment. Objective To evaluate oncologists’ views on the ethical domains of the use of AI in clinical care, including familiarity, predictions, explainability (the ability to explain how a result was determined), bias, deference, and responsibilities. Design, Setting, and Participants This cross-sectional, population-based survey study was conducted from November 15, 2022, to July 31, 2023, among 204 US-based oncologists identified using the National Plan & Provider Enumeration System. Main Outcomes and Measures The primary outcome was response to a question asking whether participants agreed or disagreed that patients need to provide informed consent for AI model use during cancer treatment decisions. Results Of 387 surveys, 204 were completed (response rate, 52.7%). Participants represented 37 states, 120 (63.7%) identified as male, 128 (62.7%) as non-Hispanic White, and 60 (29.4%) were from academic practices; 95 (46.6%) had received some education on AI use in health care, and 45.3% (92 of 203) reported familiarity with clinical decision models. Most participants (84.8% [173 of 204]) reported that AI-based clinical decision models needed to be explainable by oncologists to be used in the clinic; 23.0% (47 of 204) stated they also needed to be explainable by patients. Patient consent for AI model use during treatment decisions was supported by 81.4% of participants (166 of 204). When presented with a scenario in which an AI decision model selected a different treatment regimen than the oncologist planned to recommend, the most common response was to present both options and let the patient decide (36.8% [75 of 204]); respondents from academic settings were more likely than those from other settings to let the patient decide (OR, 2.56; 95% CI, 1.19-5.51). Most respondents (90.7% [185 of 204]) reported that AI developers were responsible for the medico-legal problems associated with AI use. Some agreed that this responsibility was shared by physicians (47.1% [96 of 204]) or hospitals (43.1% [88 of 204]). Finally, most respondents (76.5% [156 of 204]) agreed that oncologists should protect patients from biased AI tools, but only 27.9% (57 of 204) were confident in their ability to identify poorly representative AI models. Conclusions and Relevance In this cross-sectional survey study, few oncologists reported that patients needed to understand AI models, but most agreed that patients should consent to their use, and many tasked patients with choosing between physician- and AI-recommended treatment regimens. These findings suggest that the implementation of AI in oncology must include rigorous assessments of its effect on care decisions as well as decisional responsibility when problems related to AI use arise.
Quality measures in pre-liver transplant care by the Practice Metrics Committee of the American Association for the Study of Liver Diseases
Brahmania, Mayur , Kuo, Alexander , Tapper, Elliot B. , Völk, Michael , Vittorio, Jennifer , Ghabril, Marwan , Morgan, Timothy R. , Kanwal, Fasiha , Parikh, Neehar D. , Mehta, Shivang , Goldberg, David S. , Duarte‐Rojo, Andrés , Paredes, Angelo H. , Sahota, Amandeep , McElroy, Lisa M. , Thomas, Charlie, Aslam, Saima , Ramakrishnan, Sudha , Flynn, Mary M. , Volk, Michael L , Vittorio, Jennifer M , Mehta, Shivang , Winder, Scott , Im, Gene , Goldberg, David , Lai, Jennifer , Duarte-Rojo, Andres , Paredes, Angelo H , Patel, Arpan , Sahota, Amandeep , McElroy, Lisa M , Wall, Anji E , Malinis, Maricar , Aslam, Saima , Simonetto, Douglas A , Ufere, Nneka N , Ramakrishnan, Sudha , Ibrahim, Yasmin , Asrani, Sumeet K , Serper, Marina , Ghabril, Marwan S , Parikh, Neehar D , Kanwal, Fasiha , Martin, Paul B. , Winder, Gerald Scott , Lai, Jennifer C. , Patel, Arpan , Wall, Anji , Simonetto, Douglas A. , Asrani, Sumeet K. , Serper, Marina

Mayo Clinic

Hepatology | March 27, 2024 | Volume: 80 | Issue: 3 | Pages: 742-753

10.1097/hep.0000000000000870 | PMID 38536021 Get It

The liver transplantation (LT) evaluation and waitlisting process is subject to variations in care that can impede quality. The American Association for the Study of Liver Diseases (AASLD) Practice Metrics Committee (PMC) developed quality measures and patient-reported experience measures along the continuum of pre-LT care to reduce care variation and guide patient-centered care. Following a systematic literature review, candidate pre-LT measures were grouped into 4 phases of care: referral, evaluation and waitlisting, waitlist management, and organ acceptance. A modified Delphi panel with content expertise in hepatology, transplant surgery, psychiatry, transplant infectious disease, palliative care, and social work selected the final set. Candidate patient-reported experience measures spanned domains of cognitive health, emotional health, social well-being, and understanding the LT process. Of the 71 candidate measures, 41 were selected: 9 for referral; 20 for evaluation and waitlisting; 7 for waitlist management; and 5 for organ acceptance. A total of 14 were related to structure, 17 were process measures, and 10 were outcome measures that focused on elements not typically measured in routine care. Among the patient-reported experience measures, candidates of LT rated items from understanding the LT process domain as the most important. The proposed pre-LT measures provide a framework for quality improvement and care standardization among candidates of LT. Select measures apply to various stakeholders such as referring practitioners in the community and LT centers. Clinically meaningful measures that are distinct from those used for regulatory transplant reporting may facilitate local quality improvement initiatives to improve access and quality of care.
Lymphomatoid Papulosis With T-cell Receptor–Gamma Delta Expression
Guitart, Joan , Pulitzer, Melissa , Mitteldorf, Christina , Marchi, Enrica , Cropley, Thomas G., Rodríguez-Pinilla, Socorro Marıá , Griffin, Teresa, Fernandez, Rony, Tabanelli, Valentina , Borretta, Lisa, Subtil, Antonio , Piris, Jose A. Miguel Angel, Cerroni, Lorenzo , Gru, Alejandro A. , Gru, Alejandro , Tabanelli, Valentina , Mark, Erica , Kempf, Werner , Hristov, Alexandra C. , Torres‐Cabala, Carlos A. , Pileri, Stefano , Pileri, Alessandro , Plaza, Jose Antonio , Feldman, Andrew L.

Mayo Clinic

American Journal of Surgical Pathology | March 27, 2024 | Volume: 48 | Issue: 5 | Pages: 501-510

10.1097/pas.0000000000002200 | PMID 38533681 Get It

Lymphomatoid papulosis (LyP) has several histopathologic presentations. LyP featuring gamma-delta (γδ) T-cell receptor expression may masquerade as and may be misdiagnosed as aggressive cutaneous T-cell lymphoma, particularly primary cutaneous γδ T-cell lymphoma (PCGDTL) or γδ mycosis fungoides. We performed a clinicopathologic analysis of the largest series of LyP featuring γδ T-cell expression. We identified 26 patients with a diagnosis of LyP with γδ T cells from our institutions, as well as through a comprehensive review of the literature, and characterized these cases. Most cases were treated with topical steroids or not treated at all. The majority of cases showed a CD4-CD8+ phenotype and featured at least one cytotoxic marker. Histopathologic features included an intraepidermal or dermal infiltrate with large cells and frequent angiotropism. One case was initially misdiagnosed as PCGDTL, requiring further therapy. Our case series, the largest international cohort of γδ T cell predominant LyP cases, confirms marked clinicopathologic heterogeneity that may contribute to misdiagnosis, reasserting the need to identify classic clinical features, CD30+ T-cell components, and markers of cytotoxicity when dealing with this differential diagnosis. A limitation of this study includes somewhat limited follow-up, histologic, and immunophenotypic information for some cases.
Rh immune globulin immunoprophylaxis after RhD‐positive red cell exposure in RhD‐negative patients via transfusion: A survey of practices
Stephens, Laura D. , Shmookler, Aaron , O’Brien, Kerry L., Hermelin, Daniela , Bakhtary, Sara , AlMozain, Nour , Lu, Wen , Stephens, Laura , Shmookler, Aaron , O'Brien, Kerry , Karp, Julie Katz , Hermelin, Daniela , Bakhtary, Sara , Fung, Mark K , Almozain, Nour , George, Melissa

Mayo Clinic

Transfusion | March 27, 2024 | Volume: 64 | Issue: 5 | Pages: 839-845

10.1111/trf.17812 | PMID 38534065 Get It

AbstractBackgroundCurrent Association for the Advancement of Blood & Biotherapies (AABB) standards require transfusion services to have a policy on Rh immune globulin (RhIG) immunoprophylaxis for when RhD‐negative patients are exposed to RhD‐positive red cells. This is a survey of AABB‐accredited transfusion services in the United States (US) regarding institutional policies and practices on RhIG immunoprophylaxis after RhD‐negative patients receive RhD‐positive (i.e., RhD‐incompatible) packed red blood cell (pRBC) and platelet transfusions.ResultsApproximately half of the respondents (50.4%, 116/230) have policies on RhIG administration after RhD‐incompatible pRBC and platelet transfusions, while others had policies for only pRBC (13.5%, 31/230) or only platelet (17.8%, 41/230) transfusions, but not both. In contrast, 18.3% (42/230) report that their institution has no written policies on RhIG immunoprophylaxis after RhD‐incompatible transfusions. Most institutions (70.2%, 99/141) do not have policies addressing safety parameters to mitigate the risk of hemolysis associated with the high dose of RhIG required to prevent RhD alloimmunization after RhD‐incompatible pRBC transfusions.DiscussionWith approximately half of US AABB‐accredited institutions report having policies on RhIG immunoprophylaxis after both RhD‐incompatible pRBC and platelet transfusions, some institutions may not be in compliance with AABB standards. Further, most with policies on RhIG immunoprophylaxis after RhD‐incompatible pRBC transfusion do not have written safeguards to mitigate the risk of hemolysis associated with the high dose of RhIG required.ConclusionThis survey underscores the diverse and inadequate institutional policies on RhIG immunoprophylaxis after RhD exposure in Rh‐negative patients via transfusion. This observation identifies an opportunity to improve transfusion safety.
Trends and Disparities Around Cardiovascular Mortality in Sarcoidosis: Does Big Data Have the Answers?
Ahmed, Raheel , Sharma, Rakesh , Chahal, C. Anwar A. , Chahal, Choudhary Anwar A , Ahmed, Raheel , Sharma, Rakesh

Mayo Clinic

Journal of the American Heart Association | March 27, 2024 | Volume: 13 | Issue: 7 | Pages: No page available

10.1161/jaha.124.034073 | PMID 38533935 Get It

International Prognostic Score for Nodular Lymphocyte–Predominant Hodgkin Lymphoma
Binkley, Michael S. , Flerlage, Jamie E. , Savage, Kerry J. , Akhtar, Saad , Steiner, Raphaël , Zhang, Xiaoyin , Dickinson, Michael , Major, Ajay , Hendrickson, Peter G. , Hopkins, David , Ng, Andrea K. , Casulo, Carla , Baron, Jonathan , Roberts, Kenneth B. , Alkendi, Jalila , Balogh, Alex, Torka, Pallawi , Specht, Lena , Silva, Ravi De , Pickard, Keir , Henry, M M , Smith, Christine M. , Brady, J.L. , Brennan, Bernadette , Сенченко, М. А. , Reeves, Marie, Terezakis, Stephanie , Fergusson, Paige, Hawkes, Eliza A. , Lee, Denise , Barraclough, Allison , Cheah, Chan Y. , Ku, Matthew , Mutsando, Howard , Gilbertson, Michael , Marconi, Tamara , Viiala, Nicholas , Hoppe, Richard T. , Borchmann, Peter , Fuchs, Michael , Hartmann, Sylvia , Eich, Hans Theodor, Skinnider, Brian, Milgrom, Sarah A. , Alomari, Mohammed H., Advani, Ranjana H. , Metzger, Monika L. , Wirth, Andrew, Smith, Sonali M. , Koenig, Julie L. , Sakthivel, Ku G., Gao, Sarah , Rahbi, Nasser Al, Sridhar, Akshay , Shah, Nimish , Osborne, Wendy , Chang, Isabela , Miall, Fiona , Mikhaeel, G., Penn, Anthony, Pepa, Roberta Della , Opat, Stephen , Tedjaseputra, Aditya , Palese, Monica , Kelly, Kara M. , Binkley, Michael Sargent , Major, Ajay , Hopkins, David , Ng, Andrea , Casulo, Carla , Baron, Jonathan , Roberts, Kenneth B , Al Kendi, Jalila , Ricardi, Umberto , Torka, Pallawi , Specht, Lena , De Silva, Ravindu , Pickard, Keir , Blazin, Lindsay J , Smith, Christine M , Brady, Jessica , Senchenko, Maria Anatolevna , Hoppe, Bradford S , Terezakis, Stephanie A , Hawkes, Eliza , Doo, Nicole Wong , Barraclough, Allison , Cheah, Chan Yoon , Ku, Matthew , Hamad, Nada , Gilbertson, Michael , Marconi, Tamara , Maurer, Matthew , Eichenauer, Dennis A , Hoppe, Richard T , Savage, Kerry J , Advani, Ranjana H , Opat, Stephen , Dickinson, Michael , Flerlage, Jamie E , Prica, Anca A. , Casulo, Carla , Blazin, Lindsay , Henry, Michael, Halperin, Daniel M. , Hoppe, Bradford S. , Talaulikar, Dipti , Picardi, Marco , Kirova, Youlia , Doo, Nicole Wong , Hamad, Nada , Maurer, Matthew J. , Eichenauer, Dennis A. , Hodgson, David C. , Rauf, M. Shahzad , Maghfoor, Irfan , Pinnix, Chelsea C. , Vega, Francisco , Alomari, Mohammed, Collins, Graham P. , Tsang, Richard , Kelsey, Chris R. , McKay, Pamela , Constine, Louis S , Plastaras, John Peter , Levis, Mario , Sridhar, Akshay, Volchkov, Egor Vasilevich , Northend, Michael , Salvaris, Ross , Shankar, Ananth , Natkunam, Yasodha

Mayo Clinic

Journal of Clinical Oncology | March 26, 2024 | Volume: 42 | Issue: 19 | Pages: 2271-2280

10.1200/jco.23.01655 | PMID 38531001 Get It

PURPOSE Nodular lymphocyte–predominant Hodgkin lymphoma (NLPHL) is a rare cancer, and large international cooperative efforts are needed to evaluate the significance of clinical risk factors and immunoarchitectural patterns (IAPs) for all stages of pediatric and adult patients with NLPHL. METHODS Thirty-eight institutions participated in the Global nLPHL One Working Group retrospective study of NLPHL cases from 1992 to 2021. We measured progression-free survival (PFS), overall survival (OS), transformation rate, and lymphoma-specific death rate. We performed uni- and multivariable (MVA) Cox regression stratified by management to select factors for the lymphocyte-predominant international prognostic score (LP-IPS) validated by five-fold cross-validation. RESULTS We identified 2,243 patients with a median age of 37 years (IQR, 23-51). The median follow-up was 6.3 years (IQR, 3.4-10.8). Most had stage I to II (72.9%) and few B symptoms (9.9%) or splenic involvement (5.4%). IAP was scored for 916 (40.8%). Frontline management included chemotherapy alone (32.4%), combined modality therapy (30.5%), radiotherapy alone (24.0%), observation after excision (4.6%), rituximab alone (4.0%), active surveillance (3.4%), and rituximab and radiotherapy (1.1%). The PFS, OS, transformation, and lymphoma-specific death rates at 10 years were 70.8%, 91.6%, 4.8%, and 3.3%, respectively. On MVA, IAPs were not associated with PFS or OS, but IAP E had higher risk of transformation (hazard ratio [HR], 1.81; P < .05). We developed the LP-IPS with 1 point each for age ≥45 years, stage III-IV, hemoglobin <10.5 g/dL, and splenic involvement. Increasing LP-IPS was significantly associated with worse PFS (HR, 1.52) and OS (HR, 2.31) and increased risk of lymphoma-specific death (HR, 2.63) and transformation (HR, 1.41). CONCLUSION In this comprehensive study of all ages of patients with NLPHL, we develop the LP-IPS to identify high-risk patients and inform upcoming prospective clinical trials evaluating de-escalation of therapy for patients with low LP-IPS scores (<2).
Regional European genetic ancestry predicts type I interferon level and risk of severe viral infection
Nln, Ilona, Shum, Jessica, Tipon, Regine , Triese, D, Amin, Shreyasee , Osborn, Thomas G. , Chowdhary, Vaidehi , Thanarajasingam, Uma , Oke, Vilija , Gunnarsson, Iva , Zickert, A, Zervou, Maria I. , Goulielmos, George N. , Niewold, Timothy B. , Chowdhary, Vaidehi R , Svenungsson, E , Shum, J, Ghodke‐Puranik, Yogita , Makol, Ashima , Muskardin, Theresa Wampler , Boumpas, Dimitrios T.

Mayo Clinic

QJM: An International Journal of Medicine | March 26, 2024 | Volume: 117 | Issue: 8 | Pages: 581-588

10.1093/qjmed/hcae052 | PMID 38530799 Get It

Abstract Background Viral infection outcomes vary widely between individuals, ranging from mild symptoms to severe organ failure and death, and it is clear that host genetic factors play a role in this variability. Type I interferon (IFN) is a critical anti-viral cytokine, and we have previously noted differences in type I IFN levels between world populations. Methods In this study, we investigate the interrelationship between regional European genetic ancestry, type I IFN levels and severe viral infection outcomes. Results In cohorts of European ancestry lupus patients living in Europe, we noted higher IFN in the Northwestern populations as compared to Southeastern populations. In an independent cohort of European ancestry lupus patients from the USA with varying proportional regional European genetic admixture, we observed the same Northwest vs. Southeast European ancestry IFN gradient. We developed a model to predict type I IFN level based on regional European ancestry (Area under the curve (AUC) = 0.73, P = 6.1e-6). Examining large databases containing serious viral outcomes data, we found that lower predicted IFN in the corresponding European country was significantly correlated with increased viral infection fatality rate, including Coronavirus Disease 2019 (COVID-19), viral hepatitis and HIV [correlation coefficients: −0.79 (P = 4e-2), −0.94 (P = 6e-3) and −0.96 (P = 8e-2), respectively]. Conclusions This association between predicted type I IFN level and viral outcome severity suggests a potential causal relationship, as greater intrinsic type I IFN is beneficial in host defense against viruses. Genetic testing could provide insight into individual and population level risk of fatality due to viruses prior to infection, across a wide range of viral pathogens.
Two lateral flow assays for detection of anti-coccidioidal antibodies show similar performance to immunodiffusion in dogs with coccidioidomycosis
Grill, Francisca J. , Rayhel, Laura H., Lake, Douglas F. , Jaffey, Jared A. , Grys, Thomas E.

Mayo Clinic

American Journal of Veterinary Research | March 26, 2024 | Volume: 85 | Issue: 6 | Pages: No page available

10.2460/ajvr.23.12.0272 | PMID 38531155 Get It

Abstract OBJECTIVE To compare 2 point-of-care lateral flow assays (LFAs) with immunodiffusion (ID) IgG results for anti-coccidioidal antibody detection in dogs with coccidioidomycosis. A further aim was to compare the quantifiable output of 1 of the LFAs to ID antibody titers. SAMPLE Serum banked from 73 client-owned dogs diagnosed with pulmonary or disseminated coccidioidomycosis. METHODS ID was used to determine antibody presence and titer against a coccidioidal antigen preparation. All sera were subsequently tested on an LFA based on recombinant chitinase 1 (CTS1) and the commercially available sōna LFA. LFA results were analyzed and compared to ID IgG results and clinical diagnosis. RESULTS All assays showed similar sensitivities in detecting anti-coccidioidal antibodies (83.6% to 89.0%). When compared with ID IgG, the CTS1 LFA had a positive percent agreement of 100%, while the sōna LFA had a positive percent agreement of 91.4%. Since the CTS1 LFA is semiquantitative, we were able to compare test line densities with ID titers and found a strong correlation between the 2 assays (Spearman ρ = 0.82). CLINICAL RELEVANCE This is the first side-by-side evaluation of a commercially available LFA (sōna) and a newer more rapid anti-CTS1 antibody LFA using serum from dogs with coccidioidomycosis. Both LFAs tested have similar sensitivity to ID IgG results. The CTS1 LFA can be read after 10 minutes and is semiquantitative, while the sōna LFA is read after 30 minutes, and the results are subject to interpretation. Accurate and fast detection of anti-coccidioidal antibodies allows clinicians to initiate appropriate treatment without diagnostic delay.
Program Directors’ Perspectives on Residency Applications in the Post‒United States Medical Licensing Examination Step 1 Era: A Case for Standardized Letters of Recommendation?
Johny, Angeline, Chisholm, Leah , Riggs, Steve, Jackman, Stephen V. , Khan, Aqsa , Kolettis, Peter N., McNeil, Brian K. , Mayer, Wesley A. , Green, Charles E. , Khan, Aqsa A, Shenot, Patrick J. , Green, Charles

Mayo Clinic

Urology Practice | March 25, 2024 | Volume: 11 | Issue: 3 | Pages: 577-584

10.1097/upj.0000000000000556 | PMID 38526424 Get It

Advocacy Connection Team‐Now educational program for headache fellows and patients/caregivers: Assessment of educational objectives
Seebadri‐White, Courtney, Young, William B. , Arca, Karissa N., Seebadri-White, Courtney, Yuan, Hsiangkuo

Mayo Clinic

Headache: The Journal of Head and Face Pain | March 25, 2024 | Volume: 64 | Issue: 4 | Pages: 374-379

10.1111/head.14705 | PMID 38523478 Get It

Abstract Objective To assess for improvement in comfort in participating in advocacy for migraine and headache disorders and knowledge needed for successful advocacy. Background The Advocacy Connection Team (ACT)‐Now program is an educational program offered through Miles for Migraine, a non‐profit advocacy organization. It is designed to teach headache fellows and patients advocacy skills. Methods In a cross‐sectional pre‐test–post‐test design, the 2021 ACT‐Now cohort of 98 participants were administered a set of 11 pre‐course survey questions identifying their role (healthcare provider/headache fellow or patient/caregiver), baseline knowledge of migraine‐related disability and stigma, and baseline engagement and comfort with advocating. The post‐course survey questions were the same as the pre‐course questions, with the addition of one question assessing knowledge of migraine‐related disability, additional questions addressing comfort levels advocating with insurance and policymakers, as well as creating an advocacy plan. Results For the pre‐course survey, 69 participants responded and for the post‐course survey, 40 participants responded. Compared to the pre‐course survey, participants were able to correctly identify epidemiological data about migraine following the ACT‐Now course (pre‐course 46% correct, post‐course 58% correct, p = 0.263). There was also an increase in the comfort level of participants in advocacy activities, including the creation of an advocacy action plan (pre‐course 23% were “very comfortable” advocating, post‐course 63%, p < 0.05). Conclusion These results demonstrate that ACT‐Now is effective at improving advocacy skills in a mixed cohort of patients and headache fellows, giving them the skills to create advocacy plans and engage with other patients and physicians, payers, and policymakers to create a more understanding, equitable and compassionate world for persons with migraine and other headache diseases.